CD10 (Membrane Metalloendopeptidase) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone CB-CALLA ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
 
| Application  
 | IF, FC | 
|---|---|
| Primary Accession | P08473 | 
| Other Accession | 4311, 307734 | 
| Reactivity | Human | 
| Host | Mouse | 
| Clonality | Monoclonal | 
| Isotype | Mouse / IgG1, kappa | 
| Clone Names | CB-CALLA | 
| Calculated MW | 100kDa | 
| Gene ID | 4311 | 
|---|---|
| Other Names | Neprilysin, 3.4.24.11, Atriopeptidase, Common acute lymphocytic leukemia antigen, CALLA, Enkephalinase, Neutral endopeptidase 24.11, NEP, Neutral endopeptidase, Skin fibroblast elastase, SFE, CD10, MME, EPN | 
| Application Note | IF~~1:50~200 FC~~1:10~50 | 
| Storage | Store at 2 to 8°C.Antibody is stable for 24 months. | 
| Precautions | CD10 (Membrane Metalloendopeptidase) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. | 
| Name | MME {ECO:0000303|PubMed:27588448, ECO:0000312|HGNC:HGNC:7154} | 
|---|---|
| Function | Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:15283675, PubMed:6208535, PubMed:6349683, PubMed:8168535). Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond (PubMed:17101991, PubMed:6349683). Catalyzes cleavage of bradykinin, substance P and neurotensin peptides (PubMed:6208535). Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9 (PubMed:15283675, PubMed:6349683). Involved in the degradation of atrial natriuretic factor (ANF) and brain natriuretic factor (BNP(1-32)) (PubMed:16254193, PubMed:2531377, PubMed:2972276). Displays UV-inducible elastase activity toward skin preelastic and elastic fibers (PubMed:20876573). | 
| Cellular Location | Cell membrane; Single-pass type II membrane protein | 

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Recognizes a 100kDa glycoprotein, identified as CD10, also known as Common Acute Lymphocytic Leukemia Antigen (CALLA). It is a cell surface enzyme with neutral metalloendopeptidase activity, which inactivates a variety of biologically active peptides. CD10 is expressed on the cells of lymphoblastic, Burkitt’s, and follicular germinal center lymphomas, and on cells from patients with chronic myelocytic leukemia (CML). It is also expressed on the surface of normal early lymphoid progenitor cells, immature B cells within adult bone marrow and germinal center B cells within lymphoid tissue. CD10 is also present on breast myoepithelial cells, bile canaliculi, fibroblasts, with especially high expression on the brush border of kidney and gut epithelial cells.
References
Guerin S; et al. Cellular Immunology, 1997 Jan 10, 175(1):85-91. | Guerin S; et al. Faseb Journal, 1997 Apr, 11(5):376-81

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.




 
 
                                 
                                 
                                

 
                                         
                                        
 
                                         
                                         
                                         Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them. The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle. The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer. 
        

